ArticleMolecules (Basel, Switzerland)2024
Pharmacokinetics and Dose Proportionality Study of a Novel Antiparkinsonian Agent, a 1
Daria S Gorina, Anastasiya V Lastovka, Artem D Rogachev, Alexandra V Podturkina, Alla V Pavlova, Oleg V Ardashov, Nikolai S Li-Zhulanov, Tatyana G Tolstikova, Konstantin P Volcho, Nariman F Salakhutdinov
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Daria S GorinaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0009-0001-9314-0365 Anastasiya V LastovkaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Artem D RogachevN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0000-0002-3338-8529 Alexandra V PodturkinaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Alla V PavlovaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Oleg V ArdashovN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Nikolai S Li-ZhulanovN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0000-0003-3555-2481 Tatyana G TolstikovaN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Konstantin P VolchoN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.ORCID 0000-0002-4083-9324 Nariman F SalakhutdinovN. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Lavrentiev Ave., 9, 630090 Novosibirsk, Russia.
Funding
the Ministry of Science and Higher Education of the Russian Federation project 1021051402785-4-1.4.1the Ministry of Science and Higher Education of the Russian Federation project 122040400029-2the Ministry of Science and Higher Education of the Russian Federation project 122040400033-9
6 · The paper itselfAbstract
The novel antiparkinsonian agent PA-96 is the focus of our research. PA-96 supported the survival of cultured naïve dopamine neurons, alleviated motor deficits in MPTP and haloperidol-based mice models of Parkinson's disease, and increased the density of tyrosine hydroxylase positive neurons and dopamine concentration in the midbrain of an MPTP-damaged brain. In this work, an HPLC-MS/MS method was developed and validated, and the pharmacokinetics of the agent was investigated in mice after a single or multiple oral administration (
Indexed as
Antiparkinson AgentsAdministration, OralAnimalsBiological AvailabilityChromatography, High Pressure LiquidDisease Models, AnimalDose-Response Relationship, DrugMaleMiceMice, Inbred C57BLParkinson DiseaseTandem Mass SpectrometryTriazolesAntiparkinson AgentsTriazolesbioavailabilitydose proportionalityLC–MS/MSmonoterpeneParkinson’s diseasepharmacokineticvalidation
Identifiers
PMID39339493
PMCPMC11434290
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390